The objectives of the Developmental Research Program (DRP) are to continue to renew our innovative scientific endeavors within the DF/HCC Lung Cancer SPORE and to fund efforts that will complement and enhance the overall quality of the DF/HCC Lung Cancer SPORE. The Developmental Research Program will fund both established and junior investigators as we have in the past. We will set aside $50,000 per year for the Developmental Research Program Awards from SPORE funds. The DF/HCC SPORE has an extensive track record of using institutional funds to support our Developmental Research Program. This will be supplemented with an additional $250,000 per year in institutional support as we have in the past. Three to 5 individuals will be awarded each year for as much as two years of funding. The second year of funding will be dependent on making sufficient progress on review by the Developmental Research Program. The award will facilitate the research and development of independence of basic biological science, translational science, and applied science investigators within the DF/HCC Lung Cancer SPORE program. Thus, candidates will be fellows, postdoctoral fellows, and faculty within the different training programs across the Harvard campus. Success in this Developmental Research Program Will be defined as the development of innovative translational science that will generate cancer-relevant interventions in patients with lung cancer or populations at risk for lung cancer. This program will use the infrastructure created by the Administration, Evaluation and Planning Core to: 1. Solicit applications and/or identify novel research projects in the area of lung cancer 2. Evaluate these projects for financial and core support 3. Fund innovative developmental research projects 4. Monitor progress on projects for potential transition into full project status 5. Evaluate the program's success in achieving its goals as well as overall SPORE objectives

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090578-10
Application #
8377865
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
2012-07-01
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$145,734
Indirect Cost
$70,274
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Sofer, Tamar; Schifano, Elizabeth D; Christiani, David C et al. (2017) Weighted pseudolikelihood for SNP set analysis with multiple secondary outcomes in case-control genetic association studies. Biometrics 73:1210-1220
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672
Kinsey, C Matthew; San José Estépar, Raul; van der Velden, Jos et al. (2017) Lower Pectoralis Muscle Area Is Associated with a Worse Overall Survival in Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev 26:38-43
Rangachari, Deepa; VanderLaan, Paul A; Shea, Meghan et al. (2017) Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ?50% Expression in Lung Adenocarcinoma. J Thorac Oncol 12:878-883
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
VanderLaan, Paul A; Rangachari, Deepa; Mockus, Susan M et al. (2017) Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer 106:17-21
Rangachari, Deepa; Le, Xiuning; Shea, Meghan et al. (2017) Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol 12:e175-e177
Ben Khedher, Soumaya; Neri, Monica; Papadopoulos, Alexandra et al. (2017) Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium. Int J Cancer 141:309-323
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2017) Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium. Sci Rep 7:825

Showing the most recent 10 out of 256 publications